证券日报网讯2月13日，中源协和（600645）在互动平台回答投资者提问时表示，公司全资子公司武汉 光谷药业自主研发的VUM02注射液治疗特发性肺纤维化(IPF)处于I期临床试验阶段；公司参股的北京三 有利公司与首都医科大学共同申报的"人牙髓间充质干细胞注射液"治疗慢性牙周炎处于II期临床试验阶 段；公司干细胞临床研究项目已在卫生健康委/NMPA和中央军委后勤保障部完成备案。 ...

机构观点 证券之星2026年2月10日发布的估值分析显示，中源协和相对估值区间为21.33-23.58元，估值准确性评 级为C，表明当前股价偏高。基本面方面，公司行业内护城河一般，2025年前三季度营收10.92亿元，净 利润1.08亿元，盈利能力承压。机构舆情偏中性，市盈率(TTM)达161.33倍，反映市场对干细胞长期政 策红利的预期。 经济观察网近期中源协和股价呈现小幅波动。截至2026年2月11日，最新股价为25.77元，近5日累计上 涨1.70%，但20日跌幅为-6.36%。成交活跃度较低，2月11日换手率仅0.60%，日均成交额约1.2亿元。同 期医药生物板块下跌0.32%，公司股价表现略优于行业。 财报分析 2025年三季报数据显示，公司营收与利润同比双降，但第三季度单季营收降幅收窄至6.82%，归母净利 润微增3.74%，经营状况呈现边际改善。毛利率维持在69.22%的高位，经营活动现金流净额2.23亿元， 主业造血能力稳定。 以上内容基于公开资料整理，不构成投资建议。 ...

内容概要：随着生物技术的飞速发展，数字PCR仪作为新一代的核酸检测技术，正逐渐在生命科学研 究、临床诊断、食品安全检测等领域崭露头角。数字PCR仪的出现，为核酸定量分析提供了更精确、更 灵敏的方法，弥补了传统PCR技术的一些局限性，被广泛认为是PCR技术发展的重要里程碑。在过去的 几年中，中国数字PCR仪市场规模呈现出稳健的增长态势。数据显示，2019-2025年中国数字PCR仪行 业市场规模从15.84亿元增长至88.15亿元，年复合增长率为33.1%。这一增长不仅得益于技术优势的驱 动，还得益于国家政策的支持。预计未来随着数字PCR仪的不断推广和应用，科研人员、临床医生以及 相关行业从业者对其优势和应用价值的认识逐渐加深，市场接受度不断提高，将进一步推动了市场需求 的增长。 相关上市企业：迈克生物（300463）、普门科技（688389）、科华生物（002022）、安图生物 （603658）、万孚生物（300482）、亚辉龙（688575）、美康生物（300439）、九强生物（300406）、 中源协和（600645）等。 相关企业：北京新羿生物科技有限公司、臻准生物科技（上海）有限公司、领航基因科技（杭 ...

证券日报网讯1月28日，中源协和（600645）在互动平台回答投资者提问时表示，VUM03注射液是为满 足临床局部使用需求而开发的通用现货型细胞制剂，于2025年3月获批IND，用于治疗非活动性/轻度活 动性克罗恩病复杂性肛瘘。后续如有其它申报项目，公司将依据信息披露规则要求及时披露。 ...

Group 1 - The core point of the article is that Zhongyuan Qihua (中源协和) holds an 11.05% stake in Beike Biotechnology (北科生物), which is involved in a diabetes treatment project approved for trial in Hainan Boao [2] - Beike Biotechnology is a subsidiary in which Zhongyuan Qihua is a shareholder and has independent operational capabilities [2] - Investors are encouraged to follow Beike Biotechnology's official platforms for updates regarding its IPO application [2]

Core Viewpoint - The article highlights significant achievements and events within the China Shipbuilding Industry, including recognition, project completions, and internal meetings [2] Group 1 - China Shipbuilding Group's Zhihu account has been recognized as an influential government account for the year 2025 [2] - Guangzhou Shipyard International has successfully completed and delivered two vessels [2] - China Ship Asset Management (Beijing) held its 2026 annual work meeting and party building meeting [2] Group 2 - China Shipbuilding Industry held a collective birthday celebration for employees in January [2] - Waigaoqiao Shipbuilding welcomed the first snowfall of the winter season [2]

Core Viewpoint - The company, Zhongyuan Qihhe, has provided insights into its subsidiary OriGene Technologies, Inc. (OTI), highlighting its primary operations in the United States and a smaller presence in Germany [2] Group 1: Company Operations - OTI's main operational base is in the United States, focusing on the sale of research reagents [2] - The subsidiary in Germany contributes a minor portion to the overall revenue of the company [2]

Group 1 - The core point of the article is that Zhongyuan Qihhe (600645.SH) has a subsidiary, OriGene Technologies, Inc. (OTI), which primarily operates in the United States and has established a subsidiary in Germany [2] - OTI's overseas sales of research reagents are mainly focused on the U.S. market, while the German subsidiary contributes a relatively small proportion to the company's overall revenue [2]

Group 1 - The core viewpoint of the news is that Zhongyuan Xiehe's stock has shown a positive trend with a 10.16% increase year-to-date and a market capitalization of 12.99 billion yuan as of January 12 [1] - The company operates in the medical and biological industry, specifically in the field of medical devices and in vitro diagnostics, with a revenue composition primarily from testing reagents (58.46%) and cell detection preparation and storage (26.49%) [1][2] - As of September 30, 2025, Zhongyuan Xiehe reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] Group 2 - The company has not distributed any dividends in the last three years, with a total payout of 37.54 million yuan since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased by 4.06% to 34,700, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2][3] - Major shareholders include Hong Kong Central Clearing Limited, which holds 15.25 million shares, an increase of 902,300 shares compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Zhongyuan Qihua's stock has shown a slight increase of 2.02% recently, with a current trading price of 25.71 yuan per share and a total market capitalization of 12.031 billion yuan [1] - As of September 30, 2025, Zhongyuan Qihua reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] - The company's main business revenue composition includes 58.46% from testing reagents, 26.49% from cell detection preparation and storage, 11.86% from research reagents, 2.40% from genetic testing, and 0.79% from other sources [1] Group 2 - Zhongyuan Qihua operates in the medical biology sector, specifically in medical devices and in vitro diagnostics, with concepts including stem cells, assisted reproduction, biomedicine, cancer treatment, and innovative drugs [2] - The number of shareholders for Zhongyuan Qihua increased by 4.06% to 34,700 as of September 30, 2025, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2] - The company has not distributed any dividends in the last three years, with a total payout of 37.5405 million yuan since its A-share listing [3]